Evidence map›Paper›PMID 39255286›Full record

ArticlePloS one2024

A protocol for enhancing the diagnostic accuracy and predictive validity of neonatal opioid withdrawal syndrome: The utility of non-invasive clinical markers.

Sarah E Maylott, Barry M Lester, Lydia Brown, Ayla J Castano, Lynne Dansereau, Sheila E Crowell, Pascal Deboeck, Amy Salisbury, Elisabeth Conradt

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. A Comprehensive Review on Utilizing Human Brain Organoids to Study Neuroinflammation in Neurological Disorders.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sarah E MaylottDepartment of Psychiatry & Behavioral Sciences, Duke University, Durham, NC, United States of America.ORCID 0000-0002-7388-8640
Barry M LesterCenter for the Study of Children at Risk, Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Lydia BrownDepartment of Psychology, University of Utah, Salt Lake City, Utah, United States of America.
Ayla J CastanoDepartment of Psychology, University of Utah, Salt Lake City, Utah, United States of America.
Lynne DansereauCenter for the Study of Children at Risk, Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Sheila E CrowellDepartment of Psychology, University of Oregon, Eugene, Oregon, United States of America.
Pascal DeboeckCenter for the Study of Children at Risk, Alpert Medical School of Brown University, Providence, Rhode Island, United States of America.
Amy SalisburyWomen and Infants Hospital, Providence, Rhode Island, United States of America.
Elisabeth ConradtDepartment of Psychiatry & Behavioral Sciences, Duke University, Durham, NC, United States of America.

Funding

Clinical markers of neonatal opioid withdrawal syndrome: onset, severity and longitudinal neurodevelopmental outcomeR01DA049755 · NIDA · WOMEN AND INFANTS HOSPITAL-RHODE ISLAND · PI CONRADT, LIZ D, LESTER, BARRY M. · 2020 to 2024
$4.1M
NIDA NIH HHS R01 DA049755
6 · The paper itself

Abstract

Every 15 minutes in the US, an infant exposed to opioids is born. Approximately 50% of these newborns will develop Neonatal Opioid Withdrawal Syndrome (NOWS) within 5 days of birth. It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. The goals of this protocol are to use these indicators shortly after birth to differentiate newborns who will be diagnosed with NOWS from those who will have mild/no withdrawal, to determine if the indicators predict development at 6 and 18 months of age, and to increase NOWS diagnostic sensitivity for earlier, more accurate diagnoses.

Indexed as

Analgesics, OpioidBiomarkersNeonatal Abstinence SyndromeFemaleHumansInfantInfant, NewbornMaleOpioid-Related DisordersPregnancyAnalgesics, OpioidBiomarkers

Identifiers

PMID39255286
PMCPMC11386476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.